Clinical implications of human papilloma virus and other biologic markers in nasopharyngeal cancer

Kang, Hyunmo; Kwon, Minsu; Park, Jung Je; Kim, Jin Pyeong; Woo, Seung Hoon; Ahn, Seong-Ki; Lee, Jong Sil; Seo, Ji Hyun; Hwa, Jeong Seok

doi:10.1016/j.oraloncology.2016.02.002

Cited by 6 publications

(5 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The 24 studies included in the final analysis comprised 24 854 patients. Categorization of the studies by tumor site showed that there were 1474 patients with nasopharyngeal tumors, 11 458 with oral cavity tumors, 9793 with laryngeal tumors, and 2129 with hypopharyngeal tumors (Table).…”

Section: Resultsmentioning

confidence: 99%

“…We noted that some of the studies presented an unusually high prevalence of HPV-associated tumors . In those reports several HPV subtypes were included, but the threshold to measure HPV positiveness as not specified.…”

Section: Discussionmentioning

confidence: 99%

“…We noted that some of the studies presented an unusually high prevalence of HPV-associated tumors. 20,27,32,34 In those reports several HPV subtypes were included, but the threshold to measure HPV positiveness as not specified. In the oral cavity, it can be surmised that the high prevalence of HPV-associated tumors was attributed to higher T categories and to the extension of those tumors to the oropharynx.…”

Section: Favors Decreased Os Studymentioning

confidence: 99%

See 2 more Smart Citations

Survival Outcomes in Human Papillomavirus–Associated Nonoropharyngeal Squamous Cell Carcinomas

Sahovaler

Kim

Mendez

et al. 2020

JAMA Otolaryngol Head Neck Surg

View full text Add to dashboard Cite

IMPORTANCEAlthough the survival impact of human papillomavirus (HPV) in oropharyngeal squamous cell carcinoma (OPSCC) is well known, there has been conflicting and scarce evidence on the role of HPV in non-OPSCC.OBJECTIVE To undertake a Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA)-compliant systematic review and meta-analysis of all published studies on the association between HPV status and survival outcomes in patients with non-OPSCC, analyzing each site separately.DATA SOURCES PubMed, CINAHL, and Embase were searched from 1946 to December 16, 2019, for English-language articles.STUDY SELECTION Analysis comprised randomized clinical trials or observational studies that each included at least 10 patients with non-OPSCC in which the presence of HPV was analyzed, survival outcomes were reported, and a clinical follow-up of 1 year or more was performed. Studies excluded were those in which data on OPSCC and non-OPSCC were not distinguished between both cohorts and studies on patients with distant metastatic tumors at diagnosis. Final analysis included outcomes that were analyzed in at least 3 studies. DATA EXTRACTION AND SYNTHESISTwo reviewers independently abstracted the data. Risk of bias was estimated with the Newcastle-Ottawa Scale. Meta-analysis was performed using the random-effects model. MAIN OUTCOMES AND MEASURESThe primary end point was overall survival (OS); secondary end points were disease-specific survival (DSS) and disease-free survival (DFS). RESULTSOf the 3947 articles screened, a total of 22 observational and 2 randomized clinical trials were included in the analysis, representing 24 854 patients. In oral cavity locations, OS was not significantly associated with HPV positivity (hazard ratio [HR], 1.16; 95% CI, 0.83-1.61; I 2 = 71%); however, HPV-positive tumors showed worse DFS (HR, 1.81; 95% CI, 1.12-2.91; I 2 = 47%). Laryngeal and hypopharyngeal HPV-positive tumors were associated with improved OS (HR, 0.71; 95% CI, 0.54-0.92; I 2 = 38% and HR, 0.60; 95% CI, 0.47-0.76; I 2 = 0%), respectively, whereas, in nasopharyngeal locations HPV was not associated with OS (HR, 0.82; 95% CI, 0.49-1.38; I 2 = 46%) or DSS (HR, 0.55; 95% CI, 0.22-1.42; I 2 = 65%). CONCLUSIONS AND RELEVANCEIn this meta-analysis of 24 studies, HPV was associated with improved OS in laryngeal and hypopharyngeal locations but not in the oral cavity and the nasopharynx. This information may be useful for future clinical studies of laryngeal and hypopharyngeal tumors and whether HPV status should be incorporated in prognostication of patients with these cancers.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Favors Decreased Os Studymentioning

confidence: 99%

See 1 more Smart Citation

Survival Outcomes in Human Papillomavirus–Associated Nonoropharyngeal Squamous Cell Carcinomas

Sahovaler

Kim

Mendez

et al. 2020

JAMA Otolaryngol Head Neck Surg

View full text Add to dashboard Cite

show abstract

“…There have been several studies focusing on the correlation between EGFR expression and the prognosis of nasopharyngeal carcinoma, while conflicting results were reported in these studies. [ 18 , 19 ] Whether EGFR overexpression is associated with the prognosis of nasopharyngeal carcinoma remains controversial. Meanwhile, the correlation of p-EGFR (the activated form of EGFR) overexpression with the prognosis of nasopharyngeal carcinoma has also been undetermined.…”

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Prognostic value of EGFR and p-EGFR in nasopharyngeal carcinoma

Hong

Wang

et al. 2022

Medicine

View full text Add to dashboard Cite

Purpose: To evaluate the prognostic effect and clinical significance of epidermal growth factor receptor and its phosphorlated form (EGFR/p-EGFR) in nasopharyngeal carcinoma. Methods: A systematic review and meta-analysis was designed. We visited PubMed, Embase, China National Knowledge Infrastructure Database, Database of Chinese sci-tech periodicals, WanFang Database, and China Biology Medicine disc to search for Chinese and English publications of prospective studies and retrospective studies investigating the association of EGFR/p-EGFR and nasopharyngeal carcinoma prognosis from inception to April 2021. The inclusion criteria were that the samples should be pathologically confirmed as nasopharyngeal carcinoma and the expression of EGFR/p-EGFR should be detected via immunohistochemistry; the study should analyze the prognostic significance of EGFR/p-EGFR in nasopharyngeal carcinoma; hazard ratio (HR) and 95% confidence interval (CI) should be reported in the study or could be derived from survival curves; and the outcomes of the study should include overall survival (OS), disease-free survival (DFS), progression-free survival (PFS), and distant metastasis-free survival (DMFS). Results: A total of 18 studies evaluating 1451 samples were included. For studies that reported OS as an outcome, EGFR overexpression indicated worse OS of nasopharyngeal carcinoma patients. The heterogeneity between studies was high ( I 2 = 91%, P < .01), and a random-effect model was used to combine the effect size (HR = 1.71, 95% CI [1.21, 2.41], P < .01). Further sensitivity analysis and prespecified subgroup analysis were performed to detect the source of heterogeneity, and the results showed that the heterogeneity could not be eliminated. Publication bias assessed by funnel plots and Begg test and Egger test was low (Begg test: P = .846 and Egger test: P = .074). p-EGFR was not correlated with the OS of nasopharyngeal carcinoma patients (HR = 1.01, 95% CI [0.88, 1.15], P = .92). For studies that reported DFS, EGFR overexpression was associated with worse DFS in patients with nasopharyngeal carcinoma (HR = 2.53, 95% CI [1.84, 3.47], P < .01). For studies that reported PFS, EGFR overexpression was not correlated with the PFS of nasopharyngeal carcinoma patients (HR = 1.86, 95% CI [0.90, 3.82], P = .09). For studies that reported DMFS, EGFR overexpression was not correlated with the DMFS of nasopharyngeal carcinoma patients, and high heterogeneity between studies was detected ( I 2 = 97%, P < .01). A random-effect model was used to combine the effect size (HR = 1.80, 95% CI [0.56, 5.76], P = .32). A sensitivity ana...

show abstract

Is human papillomavirus and p16 expression associated with survival outcomes in nasopharyngeal cancer?

Tham

Teegala

Bardash

et al. 2018

American Journal of Otolaryngology

View full text Add to dashboard Cite

Clinical implications of human papilloma virus and other biologic markers in nasopharyngeal cancer

Cited by 6 publications

References 11 publications

Survival Outcomes in Human Papillomavirus–Associated Nonoropharyngeal Squamous Cell Carcinomas

Survival Outcomes in Human Papillomavirus–Associated Nonoropharyngeal Squamous Cell Carcinomas

Prognostic value of EGFR and p-EGFR in nasopharyngeal carcinoma

Is human papillomavirus and p16 expression associated with survival outcomes in nasopharyngeal cancer?

Contact Info

Product

Resources

About